Stip E and Lachaine. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. Ther Adv Psychopharmacol Epub ahead of print June 22 2018.
In the article, there is an error between the abstract and the text: In the abstract, it indicates that the cost savings were C$39,100. This is incorrect and instead it should be written C$35,100 in the SGA-LAI group, as indicated in the text on page 4.
Also, there are two errors in the results section of the article on page 4. It is written SD = 13.3 and SD = 29.4, instead these results should be expressed in percentages 13.3% and 29.4%, (as indicated in Table 3, on page 8) and “SD = ” should be removed.
Finally, there were two errors in Table 4. Risperidone LAI and Paliperidone LAI are second-generation antipsychotics and not first-generation antipsychotics (as incorrectly indicated in the table). Also, Haloperidol decanoate, Fluphenazine decanoate, Zuclopenthixol decanoate and Flupentixol decanoate are first-generation antipsychotics and not second-generation antipsychotics (as incorrectly indicated in the table). Risperidone LAI and Paliperidone LAI should be under the “Second-generation LAI” title; and Haloperidol decanoate, Fluhenazine decanoate, Zuclopenthixol decanoate and Flupentixol decanoate under the “First-generation LAI” title.
These errors do not change the results and the content of the study of the article.